Dr Reddys Laboratories Ltd Share Price Today - Dr Reddys Laboratories Ltd Stock Price Live NSE/BSE

Dr Reddys Laboratories Ltd

NSE: DRREDDY BSE: 500124

₹1325.50

(0.83%)

Fri, 13 Mar 2026, 10:19 pm

MTF 5xInvest in Dr Reddys Laboratories Ltd with 5x Leverage Buy with MTF

Market Cap1096.1B

PE Ratio19.54

Dividend0.61

Health Technology

Pharmaceuticals: Major

24.5K

Dr Reddys Laboratories Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
110068.55
Net Profit
5725.20
P/B
2.84
Sector P/E
32.90
P/E
16.87
EV/EBITDA
10.10
Debt/Equity (Industry)
0.16
Interest Cover (Industry)
17.01
ROCE (Industry)
16.41
RONW (Industry)
14.52
ROE
18.53
ROCE
23.05
Debt/Equity
0.11
EPS (TTM)
66.72
Dividend Yield
0.61
Book Value
431.49
Interest Cover
28.15

Analysis

all

Pros

Dividends per share have increased over the past 10 years.
Dividends paid are well covered by earnings (4.7x coverage).
Dividends after 3 years are expected to be thoroughly covered by earnings (7.2x coverage).
Dividends per share have been stable in the past 10 years.
Dr. Reddy's Laboratories's earnings growth is expected to exceed the low risk savings rate of 7.2%.

Cons

Dr. Reddy's Laboratories's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
Dr. Reddy's Laboratories's dividend is below the markets top 25% of dividend payers in India (3.08%).
Cash flow for Dr. Reddy's Laboratories is expected to increase but not above the 50% threshold in 2 years time.
Dr. Reddy's Laboratories's earnings are expected to grow by 18.3% yearly, however this is not considered high growth (20% yearly).
Dr. Reddy's Laboratories's earnings growth is positive but not above the India market average.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	26.64	26.64	26.64	26.64	26.64
FII	22.34	24.69	25.32	25.75	26.85
DII	30.44	27.98	26.74	25.62	22.90
Public	20.59	20.69	21.30	21.99	23.61
Government	0	0	0	0	0

Technical Analysis

RSI

51.79

MACD

15.31

50 DMA

1252.07

200 DMA

1263.80

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	1579.93	1420.03	1353.17	1260.13	1193.27	1100.23	940.33
Fibonacci	1420.03	1358.95	1321.22	1260.13	1199.05	1161.32	1100.23
Camarilla	1330.27	1315.62	1300.96	1260.13	1271.64	1256.98	1242.33

Pivots Level: Classic

+319.80

1579.93

+159.90

1420.03

+93.03

1353.17

1260.13

Pivot Point

LTP: 1292.30

-66.87

1193.27

-159.90

1100.23

-319.80

940.33

Moving Average

SMAEMA

Period

Value

10-EMA
1303.80
20-EMA
1292.98
30-EMA
1282.99
50-EMA
1271.05
100-EMA
1260.99
200-EMA
1255.29

Announcement Date	Purpose	Action	Ex Date
21 Jan 2026	board-meetings	Quarterly Results
10 Jun 2025	dividend	Final Dividend - Rs. - 8	10 Jul 2025
09 May 2025	agm
09 May 2025	dividend	₹8.00 Dividend /Share	10 Jul 2025
28 Sept 2024	split	Stock Split From Rs.5 to Rs.1	28 Oct 2024
28 Sept 2024	dividend	Face Value Split (Sub-Division) - From Rs 5/- Per Share To Re 1/- Per Share	28 Oct 2024
27 Jul 2024	split	1:5 Splits of Equity Shares	28 Oct 2024
16 Jun 2024	dividend	Annual General Meeting/Dividend - Rs 40 Per Share	17 Jul 2024
07 May 2024	agm
07 May 2024	dividend	₹40.00 Dividend /Share	17 Jul 2024

Dr Reddys Laboratories Ltd

Divis Laboratories Ltd

Torrent Pharmaceuticals Ltd

Lupin Ltd

Sun Pharmaceutical Industries Ltd

Cipla Ltd

Dr Reddys Laboratories Ltd About

Dr Reddys Laboratories offers a portfolio of products and services including active pharmaceutical ingredients (“APIs”), generics, branded generics, biosimilars, over the counter (“OTC”) products and pharmaceutical services.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1984

Headquarters

CEO

K Satish Reddy

Employees

Contact

Website

http://www.drreddys.com

shares@drreddys.com; mail@drreddys.com

Phone

91-40-49002900

Location

8-2-337 Road No 3, Banjara Hills, Hyderabad, Telangana, 500034

Year	History
No Result Found

Client Name	Order Side	QTY	Avg Price	Date
DR REDDYS LABORATORIES LIMITED	Buy	884213	3076.83	16 Jun 2016
THE BANK OF NEW YORK MELLON REPRESENTATIVE OFFICE	Buy	1547170	1479.21	15 Jul 2010

Dr Reddys Laboratories Ltd News

Dr. Reddy's Opens Special Window for Share Transfers

Dr. Reddy's Laboratories announces special window for re-lodgement of physical share transfer requests through newspaper advertisement as per SEBI regulations.

12 Mar 2026

companies

Dr. Reddy's Allots 10,275 Shares Under ESOP Scheme

Dr. Reddy's Laboratories allotted 10,275 equity shares to employees on March 12, 2026, under its Employee Stock Options Schemes, increasing total issued shares to 83,46,54,295.

12 Mar 2026

co actions results

Dr. Reddy's elevates M S Madhu Sundar as Global Head

Dr. Reddy's Laboratories announces elevation of M S Madhu Sundar as Global Head of Quality and PV, effective April 1, 2026, along with role changes for other senior management personnel.

10 Mar 2026

stocks

Dr. Reddy's Gets VAI Classification from USFDA

Dr. Reddy's Laboratories received USFDA Establishment Inspection Report with VAI classification for its Srikkulam facility, with inspection officially closed under 21 CFR 20.64(d)(3).

05 Mar 2026

stocks

Dr Reddy's Semaglutide Launch May Face Delays

Dam Capital flags potential delays in Dr Reddy's semaglutide launch timeline in Canada, with Sandoz projecting H2 CY26 launch instead of earlier H1 CY26 guidance for Brazil and Canada approvals.

26 Feb 2026

stocks

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800